Acute Myeloid Leukemia Not Otherwise Specified
Associated Genetic Biomarkers
NCI Definition: Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme. 
Acute myeloid leukemia not otherwise specifieds most frequently harbor alterations in DNMT3A, RUNX1, TET2, ASXL1, and SRSF2 .
DNMT3A Mutation, SRSF2 Mutation, SRSF2 Exon 1 Mutation, RUNX1 Mutation, and IDH2 Mutation are the most common alterations in acute myeloid leukemia not otherwise specified .
There is 1 clinical trial for acute myeloid leukemia not otherwise specified, of which 1 is open and 0 are completed or closed. Of the trial that contains acute myeloid leukemia not otherwise specified as an inclusion criterion, 1 is phase 2 (1 open).
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.